



regarding W_1 and W_2 , one of W_1 and W_2 is A_4 and the other is E-O-W, or when j is 1, then W_1 may be E-O-W and $A_2-C=C-W_2$ may together form a benzene ring or a heteroaryl ring having from 1 to 3, the same or different hetero atoms selected from a group consisting of a nitrogen atom, a sulfur atom and an oxygen atom (the benzene ring and the heteroaryl ring may be substituted with a nitro group, a hydroxy group, a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, an alkanoylamino group);

E represents a phenyl group optionally having from 1 to 3 groups selected from a substituent group δ , or a 5- or 6-membered monocyclic aromatic heterocyclic group having 1 or more, preferably from 1 to 3, the same or different hetero atoms selected from a group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or represents a condensed-cyclic aromatic heterocyclic group that the monocyclic aromatic heterocyclic group forms together with an aryl group;


W represents a formula (II-1):



a formula (II-2):



or a formula (II-3):



wherein G_1 and G_2 may be the same or different, each representing a lower alkyl group (the lower alkyl group may be further substituted with a halogen atom) or a cycloalkyl group, or G_1 and G_2 form, together with the nitrogen atom adjacent to G_1 and G_2 , a 5- to 8-membered aliphatic hetero-ring (the hetero-ring may have, in the ring, 1 or 2 groups of a lower alkyl group optionally substituted with a halogen atom or a halogen atom) or a bicyclo-ring; $m1$ indicates an integer of from 2 to 4; $m2$ and $m3$ each indicate an integer

of from 1 to 3; $(CH_2)_{m1}$ in the formula (II-1) may be further substituted with a lower alkyl group having from 1 to 3 carbon atoms;

wherein substituent group α is selected from: an amino group, a nitro group, a cyano group, a hydroxy group, a halogen atom, a lower alkylsulfonyl group, a lower alkyl group (the lower alkyl group may be substituted with a halogen atom), a lower cycloalkyl group (the lower cycloalkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower cycloalkoxy group (the lower cycloalkoxy group may be substituted with a halogen atom), an aryloxy group, an alaryloxy group, an aryl group, a heteroaryl group, a mono-lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a lower alkylcarboxamido group, an arylcarboxamido group, a heteroarylcarboxamido group, an alkanoyl group, and an alkylthio group;

wherein substituent group β is selected from: an amino group, a lower alkylsulfonyl group, a lower alkyl group, a lower cycloalkyl group, a lower alkoxy group, a lower cycloalkoxy group, the lower alkyl group being optionally substituted with a halogen atom, a lower cycloalkyl group (the cycloalkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom), a lower cycloalkoxy group (the lower cycloalkoxy group may be substituted with a halogen atom), a carbamoyl group, and a mono- or di-lower alkylcarbamoyl group;

wherein substituent group γ is selected from: an amino group, a nitro group, a cyano group, a hydroxy group, a lower alkylsulfonyl group, a halogen atom, a lower alkyl group (the lower alkyl group may be substituted with a halogen atom), a lower cycloalkyl group (the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group (the lower alkoxy group may be substituted with a halogen atom or a hydroxy group), a lower cycloalkoxy group (the lower alkyl group may be substituted with a halogen atom), an aryloxy group, an alaryloxy group, an aryl group, a heteroaryl group, a mono-lower alkylcarbamoyl group, a di-lower alkylcarbamoyl group, a lower alkylcarboxamido group, an arylcarboxamido group, a heteroarylcarboxamido group, an alkanoyl group, an alkylthio group, an alkoxycarbonylamino group, an alkylsulfonylamino group, an arylsulfonylamino group, and an alkylaminosulfonyl group or an arylaminosulfonyl group;

wherein substituent group δ is selected from: a halogen atom, a nitro group, a lower alkyl group, a halo-lower alkyl group, a hydroxy group, a hydroxy-lower alkyl group, a cyclo-lower alkyl group, a lower alkenyl group, a hydroxyl group, a lower alkoxy group, a halo-lower alkoxy group, a lower alkylamino group, a di-lower alkylamino group, a lower alkylthio group, a carboxyl group, a lower alkanoyl group, and a lower alkoxycarbonyl group;

or a pharmaceutically-acceptable salt thereof.

24. (New) The compound of Claim 23, wherein A_1 is a hydrogen atom, a lower alkyl group (wherein the lower alkyl group may be substituted with a halogen atom), a lower alkoxy group, a phenyl group, a pyridyl group, a carbamoyl group, a mono- or di-lower alkylcarbamoyl group, and A_2 , A_3 and A_4 each are independently a hydrogen atom or a lower alkyl group; or a pharmaceutically-acceptable salt thereof.

25. (New) The compound of Claim 23 wherein one of W_1 and W_2 is A_4 , and the other is E-O-W; or when j is 1, then W_1 is E-O-W, and A_2 -C=C- W_2 together forms a benzene ring or a heteroaryl ring having 1 or 2 nitrogen atoms in the ring; or a pharmaceutically-acceptable salt thereof.


26. (New) The compound of Claim 23 wherein E is a phenyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group or a pyrazinyl group; or a pharmaceutically-acceptable salt thereof.


27. (New) The compound of Claim 23 wherein E is a phenyl group or a pyridyl group; or a pharmaceutically-acceptable salt thereof.

28. (New) The compound of Claim 23 wherein E is a phenyl group; or a pharmaceutically-acceptable salt thereof.


29. (New) The compound of Claim 23, wherein W is the formula (II-1) or the formula (II-3).

30. (New) The compound of Claim 23, wherein the formula (I) is selected from the following formula (I-0) to (I-4):







(I-1)



(I-2)



(I-3)



(I-4)

wherein

the ring A represents a benzene ring or a heteroaryl ring having 1 or 2 nitrogen atoms in the ring (wherein the benzene ring and the heteroaryl ring is unsubstituted or substituted with a nitro group, a hydroxyl group,

a lower alkyl group, a halo-lower alkyl group, a halogen atom, a lower alkoxy group, or an alkanoylamino group), or a pharmaceutically-acceptable salt thereof.

31. (New) The compound of Claim 29, wherein the ring A is a benzene ring or a pyridine ring, or a pharmaceutically-acceptable salt thereof.

32. (New) A compound which is selected from the group consisting of:

2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 2-[4-(1-cyclopentyl-piperidin-4-yloxy)phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 3-methyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 3-ethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 7-methyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 7-(5-methyl-isoxazol-3-yl)-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 7-phenyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 3-methyl-7-phenyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 3-methyl-2-[4-(3-piperidin-1-ylpropoxy)-phenyl]-7-(pyridin-3-yl)-3aH-pyrazolo[1,5-d][1,2,4]triazine,
 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 7-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-trifluoromethyl-[1,2,4]triazolo[4,3-b]pyridazine,
 3-tert-butyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-2-yl)-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-b]pyridazine,
 7-methyl-3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-methyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 3,6-dimethyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-methyl-3-phenyl-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 4-(pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazin-6-yl)-phenol,
 4-(pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazin-6-yl)-phenol,
 3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

3-phenyl-6-[6-(3-piperidin-1-ylpropoxy)-pyridin-3-ylmethoxy]-[1,2,4]triazolo[3,4-a]phthalazine,

3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-3-yl)-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-(pyridin-2-yl)-[1,2,4]triazolo[3,4-a]phthalazine,

3-phenyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-3-trifluoromethyl-[1,2,4]triazolo[3,4-a]phthalazine,

3-tert-butyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,6-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(1-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

3-methyl-7-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine,

6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-[1,2,4]triazolo[4,3-b]pyridazine,

7-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,6-dimethyl-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-[1,2,4]triazolo[3,4-a]phthalazine,
 6-{4-[3-(2,6-dimethylpiperizin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
 6-{4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]-phe,
 N-methyl-6-[4-(3-piperidin-1-ylpropoxy)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine-3-carboxamide,
 3-(piperidin-1-ylcarbonyl)-6-[4-(3-piperidin-1-ylpropoxy)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(3-methylpiperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-{3-[(3S)-3-fluoropyrrolidin-1-yl]propoxy}-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine,
 6-{4-[3-(3-methylpiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
 6-{4-[3-(4-fluoropiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
 6-{4-[3-(3-fluoropiperidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-{3-[(2R)-(2-methylpyrrolidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-{3-[(2S)-(2-methylpyrrolidin-1-yl)propoxy]-phenyl}-[1,2,4]triazolo[4,3-b]pyridazine,
 N,N-dimethyl-6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-[1,2,4]triazolo[3,4-a]phthalazine-3-carboxamide,
 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}-phenyl]-pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,

6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,4-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-[4-(3-pyrrolidin-1-ylpropoxy)-phenyl]-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-(4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl)-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-(4-{3-[(3S)-3-methylpiperidin-1-yl]propoxy}-phenyl)-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-(4-{3-[(2R)-3-methylpyrrolidin-1-yl]propoxy}-phenyl)-pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 3-methyl-6-(4-{3-[(2R)-3-methylpyrrolidin-1-yl]propoxy}-phenyl)-pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]-3-methylpyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-isopropylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclobutylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[3,2-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[4-(1-cyclopentylpiperidin-4-yloxy)phenyl]pyrido[2,3-d][1,2,4]triazolo[4,3-b]pyridazine,
 6-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-[1,2,4]triazolo[3,4-a]phthalazine, and
 6-{6-[(3S)-3-piperidin-1-ylpropoxy]pyridin-3-yl}-[1,2,4]triazolo[3,4-a]phthalazine,
 or a pharmaceutically-acceptable salt thereof.

33. (New) A pharmaceutical composition which comprises the compound of Claim 23 or a pharmaceutically-acceptable salt thereof and a pharmaceutically acceptable carrier.

34. (New) A method for treating a metabolic system disease, a circulatory system disease or a nervous system disease in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 23 or a pharmaceutically-acceptable salt thereof.

35. (New) A method for treating a circulatory system disease selected from stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy and electrolyte metabolism disorder in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 23 or a pharmaceutically-acceptable salt thereof.

36. (New) A method for treating a nervous system disease selected from a sleep disorder, bulimia, emotional disorder, epilepsy, delirium, dementia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, recognition disorder, motion disorder, paresthesia, dysosmia, morphine resistance, narcotic dependency, alcoholic dependency and tremor in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 23 or a pharmaceutically-acceptable salt thereof.

37. (New) A method for treating a nervous system disease selected from idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insantiation, idiopathic insomnia, repetitive insomnia, true insomnia, melancholia, anxiety, schizophrenia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of Claim 23 or a pharmaceutically-acceptable salt thereof.